Hiroshi Hongo, M.D., Ph.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Taxoids | 9 | 2022 | 666 | 2.000 |
Why?
|
Prostatic Neoplasms | 12 | 2023 | 11124 | 0.840 |
Why?
|
Topoisomerase II Inhibitors | 1 | 2021 | 87 | 0.800 |
Why?
|
DNA Topoisomerases, Type II | 1 | 2021 | 121 | 0.780 |
Why?
|
Fanconi Anemia Complementation Group A Protein | 1 | 2020 | 46 | 0.720 |
Why?
|
Drug Resistance, Neoplasm | 9 | 2021 | 5172 | 0.720 |
Why?
|
Antineoplastic Agents | 12 | 2021 | 13695 | 0.620 |
Why?
|
Ureteral Neoplasms | 2 | 2016 | 111 | 0.590 |
Why?
|
Epididymitis | 1 | 2016 | 37 | 0.580 |
Why?
|
Bone Neoplasms | 3 | 2022 | 2529 | 0.440 |
Why?
|
DNA Repair | 1 | 2021 | 2046 | 0.420 |
Why?
|
Prostate | 6 | 2022 | 1774 | 0.360 |
Why?
|
Adenocarcinoma | 5 | 2021 | 6364 | 0.360 |
Why?
|
Etoposide | 2 | 2021 | 641 | 0.330 |
Why?
|
Androgen Antagonists | 2 | 2019 | 1377 | 0.320 |
Why?
|
BRCA2 Protein | 3 | 2022 | 794 | 0.300 |
Why?
|
Quinolinium Compounds | 1 | 2006 | 15 | 0.280 |
Why?
|
Carcinoma, Neuroendocrine | 2 | 2021 | 332 | 0.280 |
Why?
|
Malonates | 1 | 2006 | 42 | 0.280 |
Why?
|
Decision Support Techniques | 1 | 2016 | 1956 | 0.280 |
Why?
|
Cyclohexanones | 1 | 2006 | 30 | 0.280 |
Why?
|
Pyridinium Compounds | 1 | 2006 | 84 | 0.270 |
Why?
|
Prostate-Specific Antigen | 6 | 2022 | 2494 | 0.250 |
Why?
|
Retinoblastoma Binding Proteins | 2 | 2022 | 97 | 0.250 |
Why?
|
Nitriles | 3 | 2019 | 956 | 0.240 |
Why?
|
Cell Line, Tumor | 6 | 2021 | 16689 | 0.220 |
Why?
|
Pimozide | 1 | 2021 | 21 | 0.210 |
Why?
|
Scavenger Receptors, Class A | 1 | 2021 | 54 | 0.200 |
Why?
|
Japan | 6 | 2022 | 1360 | 0.200 |
Why?
|
Urinary Bladder Neoplasms | 3 | 2019 | 2245 | 0.190 |
Why?
|
Hypoalbuminemia | 1 | 2021 | 87 | 0.190 |
Why?
|
Hepatocyte Nuclear Factor 3-alpha | 1 | 2021 | 170 | 0.190 |
Why?
|
Receptors, Androgen | 3 | 2022 | 1058 | 0.190 |
Why?
|
Hyperuricemia | 1 | 2023 | 211 | 0.180 |
Why?
|
Octamer Transcription Factor-3 | 1 | 2021 | 223 | 0.180 |
Why?
|
Castration | 1 | 2020 | 159 | 0.180 |
Why?
|
Male | 31 | 2023 | 350118 | 0.170 |
Why?
|
PTEN Phosphohydrolase | 2 | 2022 | 1142 | 0.170 |
Why?
|
Urinary Tract | 1 | 2022 | 309 | 0.160 |
Why?
|
Tissue Adhesives | 1 | 2020 | 179 | 0.160 |
Why?
|
Severity of Illness Index | 1 | 2016 | 15540 | 0.160 |
Why?
|
Serum Albumin | 1 | 2021 | 676 | 0.160 |
Why?
|
Muscular Atrophy | 1 | 2022 | 349 | 0.160 |
Why?
|
Electron Transport Complex IV | 1 | 2018 | 189 | 0.160 |
Why?
|
Benzamides | 3 | 2019 | 1379 | 0.160 |
Why?
|
Postoperative Hemorrhage | 1 | 2021 | 413 | 0.160 |
Why?
|
Germ Cells | 1 | 2022 | 631 | 0.150 |
Why?
|
Early Detection of Cancer | 2 | 2021 | 3086 | 0.140 |
Why?
|
Carboplatin | 1 | 2019 | 801 | 0.140 |
Why?
|
Gamma Rays | 1 | 2017 | 320 | 0.130 |
Why?
|
Extracellular Signal-Regulated MAP Kinases | 1 | 2018 | 625 | 0.130 |
Why?
|
Ubiquitin-Protein Ligases | 2 | 2022 | 1861 | 0.130 |
Why?
|
Drug-Eluting Stents | 1 | 2022 | 753 | 0.130 |
Why?
|
Tumor Suppressor Protein p53 | 2 | 2022 | 2948 | 0.120 |
Why?
|
Humans | 35 | 2023 | 744343 | 0.120 |
Why?
|
Xenograft Model Antitumor Assays | 1 | 2021 | 3557 | 0.110 |
Why?
|
Quinolines | 1 | 2018 | 732 | 0.110 |
Why?
|
Neoplasm Metastasis | 2 | 2020 | 4851 | 0.110 |
Why?
|
Nephrectomy | 2 | 2016 | 1050 | 0.100 |
Why?
|
Arachidonic Acid | 1 | 2013 | 434 | 0.100 |
Why?
|
Imidazoles | 1 | 2018 | 1206 | 0.100 |
Why?
|
Ureter | 1 | 2014 | 375 | 0.100 |
Why?
|
Sequence Analysis, DNA | 2 | 2020 | 4803 | 0.100 |
Why?
|
Lung Diseases, Interstitial | 1 | 2019 | 808 | 0.100 |
Why?
|
High-Throughput Nucleotide Sequencing | 2 | 2020 | 3597 | 0.090 |
Why?
|
Cell Cycle Proteins | 1 | 2021 | 3462 | 0.090 |
Why?
|
Cell Proliferation | 3 | 2023 | 10481 | 0.090 |
Why?
|
Proto-Oncogene Proteins c-akt | 1 | 2018 | 2503 | 0.090 |
Why?
|
Epstein-Barr Virus Infections | 1 | 2015 | 570 | 0.090 |
Why?
|
Aged | 15 | 2023 | 163280 | 0.090 |
Why?
|
Carcinoma, Transitional Cell | 1 | 2016 | 808 | 0.090 |
Why?
|
Kidney Neoplasms | 2 | 2016 | 4262 | 0.090 |
Why?
|
Headache | 1 | 2017 | 1226 | 0.080 |
Why?
|
Eicosapentaenoic Acid | 1 | 2013 | 582 | 0.080 |
Why?
|
Middle Aged | 13 | 2023 | 213383 | 0.080 |
Why?
|
Signal Transduction | 3 | 2021 | 23403 | 0.080 |
Why?
|
Phosphatidylinositol 3-Kinases | 1 | 2018 | 2938 | 0.080 |
Why?
|
Gene Expression | 1 | 2021 | 7799 | 0.080 |
Why?
|
Neoplasms, Second Primary | 1 | 2016 | 1061 | 0.080 |
Why?
|
Retrospective Studies | 9 | 2022 | 77449 | 0.080 |
Why?
|
Cell Survival | 1 | 2018 | 5882 | 0.080 |
Why?
|
CD8-Positive T-Lymphocytes | 1 | 2021 | 4479 | 0.080 |
Why?
|
Laparoscopy | 1 | 2020 | 2151 | 0.080 |
Why?
|
Repressor Proteins | 1 | 2019 | 3023 | 0.080 |
Why?
|
Immunohistochemistry | 1 | 2021 | 11366 | 0.080 |
Why?
|
Urinary Tract Infections | 1 | 2013 | 788 | 0.080 |
Why?
|
Nuclear Proteins | 2 | 2019 | 5853 | 0.080 |
Why?
|
Brain Neoplasms | 2 | 2019 | 8863 | 0.070 |
Why?
|
Macrophages | 1 | 2021 | 5655 | 0.070 |
Why?
|
Organic Chemistry Phenomena | 1 | 2006 | 5 | 0.070 |
Why?
|
Feasibility Studies | 1 | 2016 | 5078 | 0.070 |
Why?
|
Lymphatic Metastasis | 1 | 2014 | 2924 | 0.070 |
Why?
|
Chemistry, Organic | 1 | 2006 | 9 | 0.070 |
Why?
|
Biopsy | 2 | 2019 | 6756 | 0.070 |
Why?
|
Phenylthiohydantoin | 2 | 2019 | 193 | 0.070 |
Why?
|
Mice | 3 | 2021 | 81183 | 0.070 |
Why?
|
Chemotherapy, Adjuvant | 1 | 2014 | 3479 | 0.070 |
Why?
|
Acute Disease | 1 | 2016 | 7149 | 0.070 |
Why?
|
Disease Models, Animal | 2 | 2021 | 18029 | 0.070 |
Why?
|
Lymphoma, Large B-Cell, Diffuse | 1 | 2015 | 1378 | 0.070 |
Why?
|
Prognosis | 4 | 2021 | 29063 | 0.070 |
Why?
|
Lung Neoplasms | 2 | 2019 | 13102 | 0.060 |
Why?
|
Anti-Bacterial Agents | 2 | 2021 | 7181 | 0.060 |
Why?
|
Kaplan-Meier Estimate | 3 | 2021 | 6538 | 0.060 |
Why?
|
Disease-Free Survival | 3 | 2022 | 6895 | 0.060 |
Why?
|
Cytokines | 1 | 2019 | 7322 | 0.060 |
Why?
|
Uricosuric Agents | 1 | 2023 | 28 | 0.060 |
Why?
|
Treatment Outcome | 6 | 2022 | 63114 | 0.060 |
Why?
|
Hypertension | 1 | 2023 | 8480 | 0.060 |
Why?
|
Age Factors | 2 | 2018 | 18370 | 0.060 |
Why?
|
Survival Analysis | 1 | 2016 | 10252 | 0.050 |
Why?
|
Cisplatin | 2 | 2019 | 1662 | 0.050 |
Why?
|
Mutation | 3 | 2022 | 29786 | 0.050 |
Why?
|
Trimethylsilyl Compounds | 1 | 2002 | 8 | 0.050 |
Why?
|
Gene Expression Profiling | 1 | 2018 | 9438 | 0.050 |
Why?
|
Butadienes | 1 | 2002 | 110 | 0.050 |
Why?
|
Protein Kinase Inhibitors | 1 | 2018 | 5535 | 0.050 |
Why?
|
Seminal Vesicles | 1 | 2021 | 101 | 0.050 |
Why?
|
Nuclear Respiratory Factor 1 | 1 | 2021 | 23 | 0.050 |
Why?
|
Sensitivity and Specificity | 1 | 2016 | 14722 | 0.050 |
Why?
|
Animals | 3 | 2021 | 168757 | 0.050 |
Why?
|
Aged, 80 and over | 6 | 2023 | 57776 | 0.050 |
Why?
|
Drug Administration Schedule | 2 | 2019 | 4933 | 0.050 |
Why?
|
Myocardial Infarction | 1 | 2021 | 11727 | 0.050 |
Why?
|
Cyanoacrylates | 1 | 2020 | 49 | 0.050 |
Why?
|
Tumor Microenvironment | 2 | 2023 | 3586 | 0.040 |
Why?
|
Acute Coronary Syndrome | 1 | 2013 | 2337 | 0.040 |
Why?
|
Ribavirin | 1 | 2021 | 395 | 0.040 |
Why?
|
Allelic Imbalance | 1 | 2019 | 77 | 0.040 |
Why?
|
Cyclin-Dependent Kinases | 1 | 2022 | 671 | 0.040 |
Why?
|
Diagnosis, Differential | 1 | 2014 | 12959 | 0.040 |
Why?
|
Quinolones | 1 | 2002 | 367 | 0.040 |
Why?
|
Adrenalectomy | 1 | 2020 | 341 | 0.040 |
Why?
|
Sutures | 1 | 2020 | 299 | 0.040 |
Why?
|
Methylprednisolone | 1 | 2019 | 387 | 0.040 |
Why?
|
Sequence Deletion | 1 | 2022 | 1526 | 0.040 |
Why?
|
Uric Acid | 1 | 2023 | 766 | 0.040 |
Why?
|
Homozygote | 1 | 2022 | 1785 | 0.040 |
Why?
|
Kallikreins | 1 | 2018 | 258 | 0.040 |
Why?
|
Polysaccharides | 1 | 2023 | 1053 | 0.030 |
Why?
|
Algorithms | 1 | 2016 | 13881 | 0.030 |
Why?
|
Risk Factors | 3 | 2016 | 72290 | 0.030 |
Why?
|
Androgens | 1 | 2022 | 1281 | 0.030 |
Why?
|
Mice, Nude | 1 | 2021 | 3689 | 0.030 |
Why?
|
Cadherins | 1 | 2019 | 907 | 0.030 |
Why?
|
Gene Knockdown Techniques | 1 | 2019 | 1655 | 0.030 |
Why?
|
Epithelial-Mesenchymal Transition | 1 | 2019 | 713 | 0.030 |
Why?
|
Multivariate Analysis | 2 | 2021 | 12245 | 0.030 |
Why?
|
Gene Expression Regulation, Neoplastic | 2 | 2021 | 8428 | 0.030 |
Why?
|
Urinalysis | 1 | 2016 | 369 | 0.030 |
Why?
|
Eleutherococcus | 1 | 2013 | 2 | 0.030 |
Why?
|
Prostatectomy | 1 | 2021 | 1890 | 0.030 |
Why?
|
Neoplastic Cells, Circulating | 1 | 2019 | 934 | 0.030 |
Why?
|
Mice, Inbred BALB C | 1 | 2021 | 6386 | 0.030 |
Why?
|
Anemia | 1 | 2021 | 1506 | 0.030 |
Why?
|
Gadolinium | 1 | 2017 | 952 | 0.030 |
Why?
|
HEK293 Cells | 1 | 2021 | 4204 | 0.030 |
Why?
|
Drugs, Chinese Herbal | 1 | 2013 | 144 | 0.030 |
Why?
|
Regression Analysis | 1 | 2021 | 6459 | 0.030 |
Why?
|
Drug Therapy, Combination | 1 | 2022 | 6489 | 0.030 |
Why?
|
Germ-Line Mutation | 1 | 2019 | 1788 | 0.030 |
Why?
|
Hydrogen-Ion Concentration | 1 | 2016 | 2557 | 0.020 |
Why?
|
Dyspnea | 1 | 2019 | 1303 | 0.020 |
Why?
|
Postoperative Complications | 1 | 2013 | 15295 | 0.020 |
Why?
|
Smoking | 2 | 2021 | 8987 | 0.020 |
Why?
|
Neoplasm Invasiveness | 1 | 2019 | 3616 | 0.020 |
Why?
|
Sequence Analysis, RNA | 1 | 2018 | 2012 | 0.020 |
Why?
|
Calcium Channel Blockers | 1 | 2013 | 690 | 0.020 |
Why?
|
RNA-Binding Proteins | 1 | 2019 | 1903 | 0.020 |
Why?
|
Glucocorticoids | 1 | 2019 | 2107 | 0.020 |
Why?
|
Escherichia coli Infections | 1 | 2013 | 532 | 0.020 |
Why?
|
Risk | 1 | 2021 | 9687 | 0.020 |
Why?
|
Platelet Aggregation Inhibitors | 1 | 2022 | 3068 | 0.020 |
Why?
|
Endothelial Cells | 1 | 2021 | 3479 | 0.020 |
Why?
|
Antigens, CD | 1 | 2019 | 4026 | 0.020 |
Why?
|
Follow-Up Studies | 2 | 2021 | 39050 | 0.020 |
Why?
|
Antibiotic Prophylaxis | 1 | 2013 | 639 | 0.020 |
Why?
|
Single-Cell Analysis | 1 | 2018 | 2183 | 0.020 |
Why?
|
Prospective Studies | 2 | 2023 | 53288 | 0.020 |
Why?
|
Renal Insufficiency, Chronic | 1 | 2021 | 2208 | 0.020 |
Why?
|
Angiotensin Receptor Antagonists | 1 | 2013 | 924 | 0.020 |
Why?
|
Neoplasm Staging | 1 | 2021 | 11031 | 0.020 |
Why?
|
Cholesterol, HDL | 1 | 2013 | 1814 | 0.020 |
Why?
|
Registries | 1 | 2021 | 8089 | 0.020 |
Why?
|
Contrast Media | 1 | 2017 | 5300 | 0.010 |
Why?
|
Neoplasm Recurrence, Local | 1 | 2021 | 9239 | 0.010 |
Why?
|
Incidence | 1 | 2021 | 20947 | 0.010 |
Why?
|
Diabetes Mellitus | 1 | 2021 | 5751 | 0.010 |
Why?
|
Atrial Fibrillation | 1 | 2021 | 5034 | 0.010 |
Why?
|
Gene Expression Regulation | 1 | 2021 | 12072 | 0.010 |
Why?
|
Phenanthridines | 1 | 2002 | 51 | 0.010 |
Why?
|
Cyclization | 1 | 2002 | 65 | 0.010 |
Why?
|
Membrane Proteins | 1 | 2019 | 7880 | 0.010 |
Why?
|
Proportional Hazards Models | 1 | 2016 | 12354 | 0.010 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 1 | 2022 | 11524 | 0.010 |
Why?
|
Coronary Angiography | 1 | 2013 | 4577 | 0.010 |
Why?
|
Escherichia coli | 1 | 2013 | 4217 | 0.010 |
Why?
|
Aspirin | 1 | 2013 | 3282 | 0.010 |
Why?
|
Hypoglycemic Agents | 1 | 2013 | 2872 | 0.010 |
Why?
|
Stereoisomerism | 1 | 2002 | 624 | 0.010 |
Why?
|
Lung | 1 | 2019 | 9856 | 0.010 |
Why?
|
Electrons | 1 | 2002 | 268 | 0.010 |
Why?
|
Female | 4 | 2023 | 380194 | 0.010 |
Why?
|
Disease Progression | 1 | 2017 | 13284 | 0.010 |
Why?
|
Magnetic Resonance Imaging | 2 | 2017 | 35421 | 0.010 |
Why?
|
Adult | 3 | 2019 | 214055 | 0.010 |
Why?
|
Tomography, X-Ray Computed | 1 | 2019 | 20129 | 0.010 |
Why?
|
Brain | 1 | 2019 | 26385 | 0.010 |
Why?
|
Neoplasms | 1 | 2021 | 21683 | 0.010 |
Why?
|